TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+9.85%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.6B
AUM Growth
+$2.6B
(+9.1%)
Cap. Flow
+$68.9M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
41.87%
Holding
156
New
13
Increased
21
Reduced
25
Closed
10
Top Buys
| 1 |
Merck
MRK
|
$28M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$21.3M |
| 3 |
Abbott
ABT
|
$18M |
| 4 |
Eli Lilly
LLY
|
$17M |
| 5 |
CVS Health
CVS
|
$16.7M |
Top Sells
| 1 |
Illumina
ILMN
|
$22.7M |
| 2 |
HCA Healthcare
HCA
|
$18.1M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$15.9M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
$15.5M |
| 5 |
STJ
St Jude Medical
STJ
|
$12.4M |
Sector Composition
| 1 | Healthcare | 91.79% |
| 2 | Real Estate | 2.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $210M | 8.09% | 2,660,131 +148,400 | +6% | +$11.7M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $155M | 5.97% | 1,484,089 +85,300 | +6% | +$8.92M |
|
3
Biogen
BIIB
$19.4B
| $151M | 5.8% | 482,033 +31,500 | +7% | +$9.86M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $100M | 3.84% | 434,086 -29,800 | -6% | -$6.86M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $93.6M | 3.6% | 764,005 +82,200 | +12% | +$10.1M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $90.1M | 3.47% | 1,033,503 | – | – |
|
7
Incyte
INCY
$16.5B
| $83M | 3.19% | 880,461 | – | – |
|
|
8
Merck
MRK
$210B
| $77.8M | 2.99% | 1,246,397 +448,800 | +56% | +$28M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $65.7M | 2.53% | 710,145 +56,300 | +9% | +$5.21M |
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $62M | 2.38% | 154,266 | – | – |
|
|
11
Abbott
ABT
$231B
| $58.3M | 2.24% | 1,378,600 +425,100 | +45% | +$18M |
|
|
12
Eli Lilly
LLY
$657B
| $57.3M | 2.2% | 713,767 +211,200 | +42% | +$17M |
|
13
Medtronic
MDT
$119B
| $53.8M | 2.07% | 623,030 -60,674 | -9% | -$5.24M |
|
14
Amgen
AMGN
$155B
| $53.7M | 2.06% | 321,640 -10,100 | -3% | -$1.68M |
|
15
UnitedHealth
UNH
$281B
| $46.4M | 1.78% | 331,100 | – | – |
|
|
SHPG
16
DELISTED
Shire pic
SHPG
| $44.9M | 1.73% | 231,413 +29,700 | +15% | +$5.76M |
|
|
17
Illumina
ILMN
$15.8B
| $44.8M | 1.72% | 246,560 -124,804 | -34% | -$22.7M |
|
18
Viatris
VTRS
$12.3B
| $43.3M | 1.66% | 1,135,552 +413,000 | +57% | +$15.7M |
|
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $40.3M | 1.55% | 331,411 +174,960 | +112% | +$21.3M |
|
20
Johnson & Johnson
JNJ
$427B
| $39.8M | 1.53% | 337,312 | – | – |
|
21
Pfizer
PFE
$141B
| $38.8M | 1.49% | 1,146,689 -336,602 | -23% | -$11.4M |
|
|
22
CVS Health
CVS
$92.8B
| $36.7M | 1.41% | 411,891 +188,000 | +84% | +$16.7M |
|
23
Teva Pharmaceuticals
TEVA
$21.1B
| $36.3M | 1.4% | 788,958 +117,000 | +17% | +$5.38M |
|
24
Neurocrine Biosciences
NBIX
$13.8B
| $33.3M | 1.28% | 656,622 -110,400 | -14% | -$5.59M |
|
25
Humana
HUM
$36.5B
| $29.2M | 1.12% | 164,800 +35,500 | +27% | +$6.28M |
|